Nektar Therapeutics (NASDAQ:NKTR – Get Rating) Director Karin Eastham sold 21,267 shares of the business’s stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $3.61, for a total transaction of $76,773.87. Following the completion of the sale, the director now owns 13,033 shares in the company, valued at approximately $47,049.13. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Nektar Therapeutics Stock Performance
NASDAQ NKTR opened at $3.66 on Friday. The business has a 50 day simple moving average of $4.13 and a 200 day simple moving average of $4.70. Nektar Therapeutics has a 52-week low of $3.02 and a 52-week high of $19.37. The stock has a market cap of $685.90 million, a price-to-earnings ratio of -1.29 and a beta of 1.16.
Nektar Therapeutics (NASDAQ:NKTR – Get Rating) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.16. Nektar Therapeutics had a negative return on equity of 82.40% and a negative net margin of 544.77%. The business had revenue of $21.59 million during the quarter, compared to analysts’ expectations of $22.75 million. During the same period in the prior year, the business earned ($0.69) EPS. Nektar Therapeutics’s revenue for the quarter was down 23.8% compared to the same quarter last year. On average, analysts predict that Nektar Therapeutics will post -2.14 EPS for the current year.
Institutional Trading of Nektar Therapeutics
Analyst Ratings Changes
Several research analysts recently issued reports on NKTR shares. StockNews.com upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 11th. JPMorgan Chase & Co. downgraded shares of Nektar Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, August 8th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Nektar Therapeutics has a consensus rating of “Hold” and an average price target of $13.17.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.
- Get a free copy of the StockNews.com research report on Nektar Therapeutics (NKTR)
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.